Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Romiplostim biosimilar - Qilu Pharmaceutical

Next Previous
Drug Profile

Romiplostim biosimilar - Qilu Pharmaceutical

Alternative Names: QL-0911; Romiplostim-N01

Latest Information Update: 15 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Qilu Pharmaceutical
  • Class Antianaemics; Carrier proteins; Immunotherapies; Recombinant fusion proteins; Skin disorder therapies
  • Mechanism of Action Thrombopoietin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Thrombocytopenia
  • Phase II Aplastic anaemia; Idiopathic thrombocytopenic purpura

Most Recent Events

  • 09 Sep 2025 Tianjin Medical University Cancer Institute and Hospital plans a clinical trial for Thrombocytopenia (SC) (NCT07162519)
  • 15 Aug 2025 Zhujiang Hospital plans a phase II trial for Thrombocytopenia (Chemotherapy-induced) in August 2025 (SC, Injection) (NCT07128576)
  • 01 Jul 2025 Cancer Institute and Hospital, Chinese Academy of Medical Sciences plans a phase II trial for Thrombocytopenia (In children, In adolescents, In adults) in China (SC), in July 2025 (NCT07043894)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top